Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page
- CheckyesterdayChange DetectedRecruitment status 'No longer looking for participants' is displayed on the study details page, and new help/navigation sections 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' have been added. The Intervention/Treatment header is updated, and the revision tag now shows v3.6.0, replacing the previous v3.5.5.SummaryDifference0.5%

- Check8 days agoChange DetectedThe page revision stamp was updated to v3.5.5, replacing the previous v3.5.4. This appears to be a backend or CMS update rather than a change to study information or features.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe revision label has been updated from v3.5.3 to v3.5.4, signaling a system update. This change does not alter the study content or its presented details.SummaryDifference0.1%

- Check51 days agoChange DetectedClinicalTrials.gov updated the page’s revision/build indicator from v3.5.2 to v3.5.3, reflecting a site version change rather than any changes to the study record.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check87 days agoChange DetectedSite revision history shows an addition of v3.5.0 and a deletion of v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.